BackgroundThe number of adults aged over 60 years with inflammatory bowel disease (IBD) is increasing. Frailty, rather than chronological age, may be a better predictor of adverse health outcomes.AimsTo summarise current knowledge about frailty in adults with IBD including the prevalence and associations of frailty and IBD‐related adverse outcomes.MethodsWe performed an electronic search of MEDLINE

BackgroundSerum hepatitis B surface antigen (HBsAg) < 100 IU/mL has been recently proposed as one of the key criteria of ‘partial cure’ in patients with chronic hepatitis B virus (HBV) infection. We analysed the clinical prognosis of hepatitis B e antigen (HBeAg)‐negative untreated patients with HBsAg < 100 IU/mL and normal alanine aminotransferase (ALT) levels.MethodsFive hundred and twenty‐one untreated

Background and AimsAlcohol use is prevalent among hepatology clinic patients with chronic liver disease (CLD). We explored factors associated with the importance and confidence dimensions of motivation to reduce drinking.MethodsParticipants (N = 121) with unhealthy alcohol use (i.e., over NIH guidelines) receiving care in hepatology clinics from a safety‐net hospital (SN, N = 54) and two Veterans Affairs

In the study by O'Connor et al. participants with primarily IBS-D undergoing a group-based education program on the British Dietary Association's advice for IBS were less likely to achieve the 12-week primary endpoint (50-point reduction in the IBS Symptom Severity Scale) if they had elevated levels of depression or anxiety at baseline [1]. We appreciate the complex undertaking of evaluating psychological

We thank Drs Katzenstein and Keefer for their editorial on our paper [1, 2]. We fully agree on the need for progress towards an integrated, personalised model of care for patients with disorders of gut-brain interaction. We are aware of the limitations of the Hospital Anxiety and Depression Scale (HADS) and concur that it does not capture all the psychological nuances seen in patients with irritable

Click on the article title to read more.

We thank Dr. Gao and Professor Segal for their interest in our paper on abdominal pain and associated factors in patients with ulcerative colitis (UC) [1, 2]. We agree with them regarding the importance of being aware of abdominal pain in patients with UC, including factors associated with gut-brain interaction, in particular anxiety and depression. Additionally, we agree with the suggestion that predictive

Pain control is often multidisciplinary and resource-intensive. Pain may be a poorly controlled symptom of ulcerative colitis (UC) culminating in significant patient dissatisfaction. The multicohort study exploring factors associated with abdominal pain in active and quiescent UC highlights the importance of attempting to prevent pain in UC. This may be achieved through understanding the risk factors

Click on the article title to read more.

The standard treatment of chronic hepatitis B virus (HBV) infection, nucleos(t)ide analogues (NUC), is usually long-term, as HBsAg loss is rarely achieved, which signifies functional cure. Recent evidence suggests that selected HBeAg-negative individuals with prolonged viral suppression and no advanced liver fibrosis can discontinue NUC therapy before HBsAg loss [1]. Studies, including a prospective

Non-selective beta-blockers (NSBBs) are highly effective in preventing variceal bleeding. They are therefore widely used in patients with liver cirrhosis and portal hypertension [1]. Since the landmark study by Lebrec et al. many studies have investigated NSBB use in cirrhosis, including the controversial paper by Serste et al. which suggested increased mortality in decompensated cirrhosis due to NSBB

At present, non-selective beta-blockers (NSBBs) are recommended for the management of clinically significant portal hypertension and primary or secondary prophylaxis of variceal bleeding in cirrhosis [1, 2]. However, as mentioned in the editorial by Alferink and de Knegt [3], the right time to discontinue NSBBs remains inconclusive. The window hypothesis, which has been for the first time proposed

Click on the article title to read more.

Click on the article title to read more.

As the global prevalence of inflammatory bowel disease (IBD) is increasing, emphasis has been placed on identifying modifiable risk factors that can aid in prevention [1]. Early-life factors, including antibiotic use and the occurrence of infections, increase the risk of developing IBD [2, 3]. This has been demonstrated in several studies, including a large-scale population-based study in Denmark,

Cirrhosis is a debilitating disease with substantial impact on health and prognosis. As the early stages of cirrhosis are asymptomatic or associated with non-specific symptoms, it was previously often diagnosed late in the disease course, after the development complications [1]. New biomarkers, liver scores and elastography have advanced noninvasive diagnosis, and the incidence and prevalence of cirrhosis

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Patients ‘lumped’ into the syndrome acute-on-chronic liver failure (ACLF) differ on several observable levels: underlying aetiology of cirrhosis, precipitants, number and severity of organ failures (OFs). Despite phenotypic heterogeneity, consensus definitions of ACLF have changed how the condition is understood, recognised and studied. A key unmet need is identifying which elements of ACLF heterogeneity

We sincerely appreciate the insightful Editorial by Sangam et al. regarding our study [1, 2]. We echo the call for harmonising definitions and prognostication in acute-on-chronic liver failure (ACLF) [3]. While the debate over definitions continues, the core concept of ACLF—a rapid deterioration due to an acute insult on chronic liver disease, with organ dysfunction and high short-term mortality—remains

Click on the article title to read more.

Click on the article title to read more.

The faecal immunochemical test (FIT) is the most used colorectal cancer (CRC) screening test worldwide [1]. FIT is a family of tests, the performance of which varies by brand, positivity threshold and testing interval [2, 3]. Despite myriad studies, the optimal FIT threshold and interval remain elusive. Countries and large health care systems that screen primarily with FIT must decide on the threshold

LINKED CONTENTThis article is linked to Allende et al paper. To view this article, visit https://doi.org/10.1111/apt.18236

Croft A, Okano S, Hartel G, Lord A, Walker G, Tambakis G, et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther. 2024; 60: 921–933. https://doi.org/10.1111/apt.18190. The units of measurement used to describe C-reactive protein (CRP) concentration in this manuscript were incorrectly reported as mg/mL. This should

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

LINKED CONTENTThis article is linked to Lee et al papers. To view these articles, visit https://doi.org/10.1111/apt.18242 and https://doi.org/10.1111/apt.18304.

Chronic liver diseases (CLDs) are a global health concern of significant magnitude, yet their true impact is often underestimated [1]. These diseases contribute to approximately two million deaths each year, accounting for around 4% of all global fatalities [2]. Despite their prevalence, CLDs frequently receive less attention compared to other major health issues. A timely study by Lee et al. which

Click on the article title to read more.

Click on the article title to read more.

This article is linked to Bak et al paper. To view this article, visit https://doi.org/10.1111/apt.18240.

This article is linked to Jiang et al paper. To view this article, visit https://doi.org/10.1111/apt.18218

Treatment approaches for inflammatory bowel disease (IBD) have changed considerably within the last two decades. Biological agents and small molecules have dramatically lifted the therapeutic ceiling. The treat-to-target concept is increasingly implemented with the latest STRIDE-II guidelines summarising the key goals as symptomatic response and remission, normalisation of C-reactive protein and decrease

We sincerely thank Vavricka et al. for their thoughtful insights on our study [1, 2]. Their editorial offers a timely and relevant discussion of topics such as mucosal healing, the top-down strategy and treatment de-escalation, all of which represent important shifts in the management of inflammatory bowel disease (IBD) [3-5]. Due to space constraints, we were unable to cover these aspects in sufficient

This article is linked to Allende et al paper. To view this article, visit https://doi.org/10.1111/apt.18236.

This article is linked to Chen et al paper. To view this article, visit https://doi.org/10.1111/apt.18131.

This article is linked to Zhao et al paper. To view this article, visit https://doi.org/10.1111/apt.18217.

This article is linked to Vargas-Accarino et al paper. To view this article, visit https://doi.org/10.1111/apt.18227.